Statin therapy is associated with lower prevalence of gut microbiota dysbiosis
Artikel i vetenskaplig tidskrift, 2020

Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n = 2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics.

Författare

Sara Vieira-Silva

KU Leuven

Gwen Falony

KU Leuven

Eugeni Belda

Université Pierre et Marie Curie (UPMC)

Trine Nielsen

Köpenhamns universitet

Judith Aron-Wisnewsky

Université Pierre et Marie Curie (UPMC)

Rima Chakaroun

Universität Leipzig

Sofia K. Forslund

Max Delbrueck Centrum Fuer Molekulare Medizin

Karen Assmann

Université Pierre et Marie Curie (UPMC)

Mireia Vallès-Colomer

KU Leuven

Thi Thuy Duyen Nguyen

KU Leuven

Sebastian Proost

KU Leuven

Edi Prifti

Université Pierre et Marie Curie (UPMC)

Valentina Tremaroli

Wallenberg Lab.

Nicolas Pons

Université Paris-Saclay

Emmanuelle Le Chatelier

Université Paris-Saclay

Fabrizio Andreelli

Université Pierre et Marie Curie (UPMC)

Jean-Phillippe Bastard

Assistance publique – Hôpitaux de Paris (AP-HP)

Luis P. Coelho

European Molecular Biology Laboratory

Nathalie Galleron

Université Paris-Saclay

Tue H. Hansen

Köpenhamns universitet

Jean-Sébastien Hulot

Assistance publique – Hôpitaux de Paris (AP-HP)

Christian Lewinter

Köpenhamns universitet

Helle K. Pedersen

Köpenhamns universitet

Benoit Quinquis

Université Paris-Saclay

Christine Rouault

Université Pierre et Marie Curie (UPMC)

Hugo Roume

Université Paris-Saclay

Joe-Elie Salem

Assistance publique – Hôpitaux de Paris (AP-HP)

Nadja B. Søndertoft

Köpenhamns universitet

Sothea Touch

Université Pierre et Marie Curie (UPMC)

Renato Alves

European Molecular Biology Laboratory

Chloe Amouyal

Université Pierre et Marie Curie (UPMC)

Ehm Astrid Andersson Galijatovic

Köpenhamns universitet

Olivier Barthelemy

Assistance publique – Hôpitaux de Paris (AP-HP)

Jean-Paul Batisse

Assistance publique – Hôpitaux de Paris (AP-HP)

Magalie Berland

Université Paris-Saclay

Randa Bittar

Assistance publique – Hôpitaux de Paris (AP-HP)

Hervé Blottière

Université Paris-Saclay

Frederic Bosquet

Assistance publique – Hôpitaux de Paris (AP-HP)

Rachid Boubrit

Assistance publique – Hôpitaux de Paris (AP-HP)

Olivier Bourron

Assistance publique – Hôpitaux de Paris (AP-HP)

Mickael Camus

Université Paris-Saclay

Dominique Cassuto

Assistance publique – Hôpitaux de Paris (AP-HP)

Cecile Ciangura

Assistance publique – Hôpitaux de Paris (AP-HP)

Jean-Philippe Collet

Assistance publique – Hôpitaux de Paris (AP-HP)

Maria-Carlota Dao

Université Pierre et Marie Curie (UPMC)

Jean Debedat

Université Pierre et Marie Curie (UPMC)

Morad Djebbar

Assistance publique – Hôpitaux de Paris (AP-HP)

Angélique Doré

Université Paris-Saclay

Line Engelbrechtsen

Köpenhamns universitet

Soraya Fellahi

Assistance publique – Hôpitaux de Paris (AP-HP)

Sebastien Fromentin

Université Paris-Saclay

Philippe Giral

Assistance publique – Hôpitaux de Paris (AP-HP)

Marianne Graine

Integromics Unit

Agnes Hartemann

Assistance publique – Hôpitaux de Paris (AP-HP)

Bolette Hartmann

Köpenhamns universitet

Gerard Helft

Assistance publique – Hôpitaux de Paris (AP-HP)

Serge Hercberg

U1153 INSERM

Malene Hornbak

Köpenhamns universitet

Richard Isnard

Assistance publique – Hôpitaux de Paris (AP-HP)

Sophie Jaqueminet

Assistance publique – Hôpitaux de Paris (AP-HP)

Niklas Rye Jørgensen

Köpenhamns universitet

Hanna Julienne

Université Paris-Saclay

Johanne Justesen

Köpenhamns universitet

Judith Kammer

Universität Leipzig

Mathieu Kerneis

Assistance publique – Hôpitaux de Paris (AP-HP)

Jean Khemis

Assistance publique – Hôpitaux de Paris (AP-HP)

Nikolaj Krarup

Köpenhamns universitet

Michael Kuhn

European Molecular Biology Laboratory

Aurélie Lampuré

Université Pierre et Marie Curie (UPMC)

Véronique Lejard

Université Paris-Saclay

Florence Levenez

Université Paris-Saclay

Lea Lucas-Martini

Assistance publique – Hôpitaux de Paris (AP-HP)

Robin Massey

Université Paris-Saclay

Nicolas Maziers

Université Paris-Saclay

Jonathan Medina-Stamminger

Assistance publique – Hôpitaux de Paris (AP-HP)

Lucas Moitinho-Silva

European Molecular Biology Laboratory

Gilles Montalescot

Assistance publique – Hôpitaux de Paris (AP-HP)

Sandrine Moutel

Assistance publique – Hôpitaux de Paris (AP-HP)

Laetitia Pasero Le Pavin

Université Paris-Saclay

Christine Poitou-Bernert

Université Pierre et Marie Curie (UPMC)

Francoise Pousset

Assistance publique – Hôpitaux de Paris (AP-HP)

Laurence Pouzoulet

Assistance publique – Hôpitaux de Paris (AP-HP)

Sebastian Schmidt

European Molecular Biology Laboratory

Johanne Silvain

Assistance publique – Hôpitaux de Paris (AP-HP)

Mathilde Svendstrup

Köpenhamns universitet

Timothy Swartz

Université Pierre et Marie Curie (UPMC)

Thierry Vanduyvenboden

Université Paris-Saclay

Camille Vatier

Assistance publique – Hôpitaux de Paris (AP-HP)

Eric Verger

Université Pierre et Marie Curie (UPMC)

Stefanie Walther

Universität Leipzig

Marc-Emmanuel Dumas

Imperial College London

Stanislav Dusko Ehrlich

Université Paris-Saclay

Pilar Galan

U1153 INSERM

Jens P. Gøtze

Köpenhamns universitet

Torben Hansen

Köpenhamns universitet

Jens Juul Holst

Köpenhamns universitet

Lars Køber

Köpenhamns universitet

Ivica Letunic

Biobyte Solutions

Jens B Nielsen

Chalmers, Biologi och bioteknik, Systembiologi

Jean-Michel Oppert

Assistance publique – Hôpitaux de Paris (AP-HP)

M. Stumvoll

Universität Leipzig

H. Vestergaard

Köpenhamns universitet

Jean-Daniel Zucker

Université Pierre et Marie Curie (UPMC)

Peer Bork

European Molecular Biology Laboratory

O. B. Pedersen

Köpenhamns universitet

Fredrik Bäckhed

Köpenhamns universitet

K. Clement

Université Pierre et Marie Curie (UPMC)

Jeroen Raes

KU Leuven

Nature

0028-0836 (ISSN) 1476-4687 (eISSN)

Vol. 581 7808 310-315

Ämneskategorier

Bioinformatik och systembiologi

DOI

10.1038/s41586-020-2269-x

PubMed

32433607

Mer information

Senast uppdaterat

2022-02-01